Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of TOX versus EOX in advanced unresectable or metastatic gastric cancer
2008-004996-24Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria delle Marche
- Start
- Oct 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, epirubicin, oxaliplatin and capecitabine in gastric adenocarcinoma (2 arms), sponsored by Azienda Ospedaliero-Universitaria delle Marche. Primary endpoint: Overall response rate. Started Oct 2008; status: active.
02
Drugs
docetaxelepirubicinoxaliplatincapecitabine
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2008-004996-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004996-24.